Karyopharm Therapeutics Inc (NASDAQ: KPTI) shares are trading higher after the FDA granted Fast Track Designation to the development program of selinexor for myelofibrosis, including primary myelofibrosis, post-essential thrombocythemia myelofibrosis, and post-
EVgo reported Q1 FY24 earnings, surpassing estimates with a 118.2% Y/Y sales growth to $55.2 million. The uptick in revenue, fueled by charging and eXtend services, reflects the company's accelerating network throughput, hitting 53 GWh, a 194% Y/Y increase.